First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation

ConclusionsFor patients with untreated, advanced,EGFR-mutation –harboring NSCLCs, the anti-VEGF + erlotinib combination, compared to erlotinib alone, was associated with significantly prolonged PFS but mature data for OS are needed to confirm the benefit of this strategy.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research